Loflor – Redle Pharmaceuticals

Opposed App ID 6228914 Class 5 Word

Trademark information

IP India · live record
Application ID
6228914
Status
Opposed
Sub status
Not Applicable
Date of application
21 December 2023
Classes
5
Type
Word
Proprietor
Redle Pharmaceuticals Private 301 302, 3rd Floor, Kunthu Commerce Centre, Plot No. 174, Bangur Nagar, Goregaon –West, Mumbai 400104, Maharashtra
Attorney
G L Verma[19424]Verma & Co, 221, V. B. Plaza, Plot 10, Pkt 7, Opp. Metro, Sector 12, Dwarka, New Delhi 110078
State
Maharashtra
Filing mode
e-Filing
IP office
Mumbai
Used since
29 January 2018
Valid / upto
—

Goods & services

Class 5

Class 5PHARMACEUTICAL, MEDICINALPREPARATION AND FORMULATION

Uploaded documents

Sign in to open
1 TM-A(TRADE MARKS APPLICATION) 21 Dec 2023
2 Reply to Exam Report (MIS-R) 01 Feb 2024
3 TM-M(CORRECTION OF CLERICAL ERROR OR FOR AMENDMENT U/R 37) 19 Nov 2025
4 Documents in support of Show cause Hearing (SCH) 12 Dec 2025
5 TM-O(NOTICE OF OPPOSITION) 15 Jan 2026
6 Journal Copy 18 Mar 2026
7 TM-O(NOTICE OF OPPOSITION) 13 Apr 2026
8 TM-O(NOTICE OF OPPOSITION) 29 Apr 2026
9 TM-M(CORRECTION OF CLERICAL ERROR OR FOR AMENDMENT U/R 37) 23 May 2026
10 Annexure -1 under rule 46 01 Jun 2026
11 Evidence Affidavit Under Rule 46 (TOP) 01 Jun 2026

Correspondence and notices

1 EXAMINATION REPORT 16909935 22 Dec 2023
2 Hearing Notice for Application No. 6228914 21025383 15 Oct 2025
3 Tribunal Accepted Notice for : 6228914 21364447 · 7527439 18 Dec 2025
4 Opposition Notice 21612153 · 7577359 20 Jan 2026
5 Opposition Counter Statement 22225217 · 7730675 01 Apr 2026
6 Opposition Notice 22410664 · 7779747 22 Apr 2026
7 Opposition Notice 22583776 · 7824289 12 May 2026
8 Generate Report 23530126 · 7972511 06 Aug 2026
9 Generate Report 23530144 · 7972512 06 Aug 2026

Frequently asked questions

Loflor was applied for on 21 December 2023.

The application was filed by Redle Pharmaceuticals.

Class 5.

As per IP India, the status is Opposed.

The listed application ID of Loflor is 6228914.

Trademark attorney G L Verma.